Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of December 2022. The report details a specific corporate action involving the transfer of treasury shares to satisfy employee equity awards under the company's Deferred Annual Bonus Plan, Performance Share Plan, and Share Value Plan.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to the specific share transaction:
- Shares Transferred: 26,800,000 Ordinary Shares.
- ADRs Issued: 13,400,000 American Depositary Receipts.
- Consideration Received: $34.590 per ADR ($17.295 per Ordinary Share).
- Funding Source: Contribution from GlaxoSmithKline LLC to the Trust.
Material Changes
Following the transfer on December 1, 2022, the company's capital structure was updated as of December 2, 2022:
- Total Issued Share Capital: 4,311,323,691 Ordinary Shares.
- Treasury Shares Held: 217,124,760 Ordinary Shares.
- Total Voting Rights: 4,094,198,931.
This updated voting rights figure serves as the denominator for shareholder notification calculations under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. The document is strictly a notification of a treasury share transfer.
Investor Verification Checklist
- Verify the updated total voting rights count of 4,094,198,931 for compliance with disclosure thresholds.
- Confirm the reduction in treasury shares from prior reporting periods to 217,124,760.
- Note that this transaction was funded by GlaxoSmithKline LLC rather than direct cash proceeds from the market.